Anti-inhibitor coagulant complex Disease Interactions

The use of anti- inhibitor coagulant complex is contraindicated in patients with significant signs of fibrinolysis, disseminated intravascular coagulation (DIC), and acute thrombosis or embolism including myocardial infarction. Anti- inhibitor coagulant complex contains Factor VIII inhibitor bypassing activity and prothrombin complex factors and may cause or exacerbate fibrinolysis or coagulation. If DIC or fibrinolysis occurs during treatment, the infusion should be stopped promptly and appropriate therapeutic measures initiated. Thromboembolic events may also occur during treatment, particularly following the administration of large doses and/or in patients with thrombotic risk factors. Caution is advised when administering anti- inhibitor coagulant complex to patients with an active or past history of thromboembolic disorders.